Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Biovail Corporation and Others
2003年11月14日 - 6:40AM
PRニュース・ワイアー (英語)
Schatz & Nobel, P.C. Announces Class Action Lawsuit Against
Biovail Corporation and Others HARTFORD, Conn., Nov. 13
/PRNewswire/ -- A lawsuit seeking class action status has been
filed in the United States District Court for the Southern District
of New York on behalf of all persons who purchased the common
shares of Biovail Corporation (NYSE: BVF; TSX: BVF) ("Biovail" or
the "Company") between February 7, 2003 and October 30, 2003 (the
"Class Period" or the "Class") for violations of the federal
securities laws. Biovail's common shares are traded on the New York
Stock Exchange and on the Toronto Stock Exchange under the symbol
"BVF." Plaintiff is represented by the law firm of Schatz &
Nobel, P.C., which has significant experience prosecuting class
actions on behalf of investors. If you wish to discuss this action
or have any questions, please contact attorney Andrew M. Schatz,
Jeffrey S. Nobel, or Nancy A. Kulesa at (800) 797- 5499, or by
e-mail at . For more information about Schatz & Nobel, P.C. and
class action cases, please visit our website:
http://www.snlaw.net/. The Complaint alleges that Biovail and
certain of its officers and directors made materially false and
misleading statements during the Class Period. Specifically,
Defendants made material misrepresentations concerning Biovail's
financial results and business by, inter alia, improperly reporting
revenue and earnings attributable to the sales of a generic version
of Prilosec and misstating the demand in the marketplace for that
product. Plaintiff further alleges that these material
misrepresentations artificially inflated the price of Biovail's
common shares, which traded as high as $50.30 on the New York Stock
Exchange and as high as CD $67.75 on the Toronto Stock Exchange
during the Class Period. Plaintiff seeks to recover damages on
behalf of all Class Members, including Class Members that purchased
Biovail common shares on the Toronto Stock Exchange. If you
purchased or otherwise acquired Biovail common shares between
February 7, 2003 and October 30, 2003, and wish to act as a lead
plaintiff, you may move the Court to act in that capacity not later
than January 12, 2004. If you wish to discuss your rights as lead
plaintiff or as a class member, please contact Schatz & Nobel,
P.C. toll-free at (800) 797- 5499, or by e-mail at . CONTACT:
Andrew M. Schatz Jeffrey S. Nobel Nancy A. Kulesa Tel.: (800)
797-5499 Website: http://www.snlaw.net/ e-mail: DATASOURCE: Schatz
& Nobel, P.C. CONTACT: Andrew M. Schatz, Jeffrey S. Nobel or
Nancy A. Kulesa, all of Schatz & Nobel, P.C., +1-800-797-5499,
Web site: http://www.snlaw.net/
Copyright